Allostery Investments LP

CIK

1978599

Location

Stamford, CT

Portfolio Value

Micro $4,580,743

Diversification

Diversified

Filing Date

Global Rank

#8,056 / 8,120 ▼ 189 · as of Jun 2025

Top Industry

Biotechnology 71.1%

3Y Alpha vs SPY

+245.8%

Period ended 1 year ago

Filed Aug 14, 2025 · 1y

3 quarters · since Dec 2024

Clone Performance

Feb 2025–Jan 2026 · vs SPY

Hypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.

Not a measure of this manager's performance. Most of Allostery Investments LP's reported book is option positions, which a stock-only clone cannot replicate. The figures below are the return of the 82% that is ordinary stock — as little as 45% in one quarter — so a manager whose options thesis lost money can still show a large gain here.

Cloned portfolio

+220.2%

SPY

+13.8%

Annualised alpha

+245.8%

Max drawdown

−27.7%

Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Captured split ratios restate closes onto one basis; only an unusable ratio can exclude earlier closes for that listing. It tracks 82% of reported value on average across 3 quarters.Allostery Investments LP has stopped filing, so the simulation ends in Jan 2026 — where its last reported portfolio went stale — rather than trading that portfolio forward to today. Past performance does not predict future results.

Portfolio Concentration

18 tracked positions · as of Jun 30, 2025 · Δ vs Mar 31, 2025

Top Position

27.9%

+11.1 pts

Top 5

74.5%

+18.8 pts

Top 10

95.1%

+15.8 pts

HHI

1,479

Diversified+646

Portfolio Trend

3 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2025

Sector	% Portfolio	Value	Positions
Healthcare	100.0%	$4,580,743	16
Unclassified	0.0%	$0	2

Last Quarter's Activity

Export CSV

Jun 30, 2025 vs Mar 31, 2025

Added To

Positions the filer increased

1 positions

Ticker	Company	Δ Shares	Shares	Value	Open
—		+4,500	22,500	$0
No positions match the current search.

Trimmed

Positions the filer reduced

13 positions

Ticker	Company	Δ Shares	Shares	Value
ABVX	Abivax S.A.	−932,304	167,350	$1,280,227
—		−418,302	40,000	$0
EOLS	Evolus, Inc.	−352,754	60,000	$552,600
CNTA	Centessa Pharmaceuticals plc	−330,024	52,500	$0
AMLX	Amylyx Pharmaceuticals, Inc.	−145,980	120,119	$769,962
—		−115,657	9,000	$0
APGE	Apogee Therapeutics, Inc.	−104,000	6,000	$260,580
AVTX	Avalo Therapeutics, Inc.	−98,141	9,000	$44,910
PMN	ProMIS Neurosciences Inc.	−77,983	155,720	$74,745
BBIO	BridgeBio Pharma, Inc.	−76,000	4,000	$172,720
CYTK	Cytokinetics Inc	−65,000	5,000	$165,200
—		−43,000	1,000	$0
LEGN	Legend Biotech Corp	−750	4,000	$141,960
No positions match the current search.

New Positions

Positions the filer opened this quarter

4 positions

Ticker	Company	Shares	Value
RZLT	Rezolute, Inc.	119,294	$532,051
FULC	Fulcrum Therapeutics, Inc.	40,353	$277,628
TNGX	Tango Therapeutics, Inc.	40,000	$204,800
NKTR	Nektar Therapeutics	4,000	$103,360
No positions match the current search.

Sold Out

Positions the filer fully exited

25 positions

Ticker	Company	Shares	Value
ALKS	Alkermes plc.	115,000	$3,797,300
ZURA	Zura Bio Ltd	2,329,384	$3,004,905
BEAM	Beam Therapeutics Inc.	92,754	$1,811,485
PCVX	Vaxcyte, Inc.	32,000	$1,208,320
IONS	Ionis Pharmaceuticals Inc	35,000	$1,055,950
XENE	Xenon Pharmaceuticals Inc.	30,000	$1,006,500
INSM	INSMED Inc	10,000	$762,900
TARS	Tarsus Pharmaceuticals, Inc.	13,600	$698,632
GOSS	Gossamer Bio, Inc.	613,028	$674,330
PLRX	Pliant Therapeutics, Inc.	441,686	$596,276
CNTX	Context Therapeutics Inc.	950,166	$581,501
RLYB	Rallybio Corp	752,235	$492,713
ELDN	Eledon Pharmaceuticals, Inc.	100,000	$339,000
CLYM	Climb Bio, Inc.	244,988	$298,885
ORKA	Oruka Therapeutics, Inc.	20,000	$205,200
MDGL	Madrigal Pharmaceuticals, Inc.	600	$198,738
VIR	Vir Biotechnology, Inc.	22,202	$143,868
WVE	Wave Life Sciences, Inc.	17,500	$141,400
ARQT	Arcutis Biotherapeutics, Inc.	7,500	$117,300
EWTX	Edgewise Therapeutics, Inc.	3,000	$66,000
LXEO	Lexeo Therapeutics, Inc.	5,054	$17,537
JBIO	Jade Biosciences, Inc.	1,421,568	$0
—		25,000	$0
—		52,500	$0
PHGE	BiomX Inc.	940,629	$0
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

18 tracked positions · $4,580,743 total · filing declares 20 positions · $7,850,255 · as of Jun 30, 2025

All sectors Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	% of Portfolio
ABVX	Abivax S.A. Healthcare	Reduced	167,350	-932,304	$1,280,227	−81.4%	27.95%
AMLX	Amylyx Pharmaceuticals, Inc. Healthcare	Reduced	120,119	-145,980	$769,962	−18.3%	16.81%
EOLS	Evolus, Inc. Healthcare	Reduced	60,000	-352,754	$552,600	−88.9%	12.06%
RZLT	Rezolute, Inc. Healthcare	NEW	119,294	NEW	$532,051	NEW	11.61%
FULC	Fulcrum Therapeutics, Inc. Healthcare	NEW	40,353	NEW	$277,628	NEW	6.06%
APGE	Apogee Therapeutics, Inc. Healthcare	Reduced	6,000	-104,000	$260,580	−93.7%	5.69%
TNGX	Tango Therapeutics, Inc. Healthcare	NEW	40,000	NEW	$204,800	NEW	4.47%
BBIO	BridgeBio Pharma, Inc. Healthcare	Reduced	4,000	-76,000	$172,720	−93.8%	3.77%
CYTK	Cytokinetics Inc Healthcare	Reduced	5,000	-65,000	$165,200	−94.1%	3.61%
LEGN	Legend Biotech Corp Healthcare	Reduced	4,000	-750	$141,960	−11.9%	3.10%
NKTR	Nektar Therapeutics Healthcare	NEW	4,000	NEW	$103,360	NEW	2.26%
PMN	ProMIS Neurosciences Inc. Healthcare	Reduced	155,720	-77,983	$74,745	−54.3%	1.63%
AVTX	Avalo Therapeutics, Inc. Healthcare	Reduced	9,000	-98,141	$44,910	−94.8%	0.98%
		Added	22,500	+4,500	$0	—	0.00%
		Reduced	40,000	-418,302	$0	—	0.00%
CNTA	Centessa Pharmaceuticals plc Healthcare	Reduced	52,500	-330,024	$0	—	0.00%
		Reduced	1,000	-43,000	$0	—	0.00%
		Reduced	9,000	-115,657	$0	—	0.00%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.